129 related articles for article (PubMed ID: 16525816)
1. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
Pai SM; Yamada H; Murata H
Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
[TBL] [Abstract][Full Text] [Related]
3. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
4. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
[TBL] [Abstract][Full Text] [Related]
7. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
[TBL] [Abstract][Full Text] [Related]
8. An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes.
Custodio JM; Donaldson KM; Hunt HJ
J Clin Pharmacol; 2021 Feb; 61(2):244-253. PubMed ID: 32869328
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Tachibana M; Papadopoulos KP; Strickler JH; Puzanov I; Gajee R; Wang Y; Zahir H
Br J Clin Pharmacol; 2018 Jan; 84(1):112-121. PubMed ID: 28865153
[TBL] [Abstract][Full Text] [Related]
11. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.
Stage TB; Graff M; Wong S; Rasmussen LL; Nielsen F; Pottegård A; Brøsen K; Kroetz DL; Khojasteh SC; Damkier P
Br J Clin Pharmacol; 2018 Mar; 84(3):510-519. PubMed ID: 29105855
[TBL] [Abstract][Full Text] [Related]
12. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.
Qiu JX; Zhou ZW; He ZX; Zhang X; Zhou SF; Zhu S
Drug Des Devel Ther; 2015; 9():841-66. PubMed ID: 25733806
[TBL] [Abstract][Full Text] [Related]
15. The Development and Validation of a Novel "Dual Cocktail" Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions.
Kwon M; Jeon JH; Choi MK; Song IS
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33007943
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers.
Stoll F; Blank A; Mikus G; Czock D; Weiss J; Meyer-Tönnies MJ; Gümüs KS; Tzvetkov M; Burhenne J; Haefeli WE
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):101-109. PubMed ID: 38114885
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.
Adedoyin A; Frye RF; Mauro K; Branch RA
Br J Clin Pharmacol; 1998 Sep; 46(3):215-9. PubMed ID: 9764961
[TBL] [Abstract][Full Text] [Related]
18. Potential inhibition of major human cytochrome P450 isoenzymes by selected tropical medicinal herbs-Implication for herb-drug interactions.
Showande SJ; Fakeye TO; Kajula M; Hokkanen J; Tolonen A
Food Sci Nutr; 2019 Jan; 7(1):44-55. PubMed ID: 30680158
[TBL] [Abstract][Full Text] [Related]
19. The effects of acute hydrogen sulfide poisoning on cytochrome P450 isoforms activity in rats.
Wang X; Chen M; Chen X; Ma J; Wen C; Pan J; Hu L; Lin G
Biomed Res Int; 2014; 2014():209393. PubMed ID: 24790991
[TBL] [Abstract][Full Text] [Related]
20. Integrated Use of In Vitro and In Vivo Information for Comprehensive Prediction of Drug Interactions Due to Inhibition of Multiple CYP Isoenzymes.
Hozuki S; Yoshioka H; Asano S; Nakamura M; Koh S; Shibata Y; Tamemoto Y; Sato H; Hisaka A
Clin Pharmacokinet; 2023 Jun; 62(6):849-860. PubMed ID: 37076696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
